Curing Price Pain: The central government is contemplating to give big relief to the common people troubled by expensive medicines. The prices of popular and high-demand anti-diabetic and anti-bacterial drugs may come down soon, as the Narendra Modi government at the Center plans to review the National List of Essential Medicines (NLEM) based on market sales. Is.
According to News18.com, the government is considering bringing highly priced and popular drugs such as the anti-diabetic drug sitagliptin, the widely used anti-bacterial injectable meropenem and the drug cefpodoxime under the price control.
Sources told News18 that major changes have been demanded by Union Health Minister Mansukh Mandaviya. “The data has been submitted by the Bureau of Pharma PSUs of India and is being reviewed by the National Pharmaceutical Pricing Authority (NPPA) for further suggestions to the minister’s office,” an official said.
RRB-NTPC Result Row: AISA called for ‘Bihar Bandh’ on 28 January, warning students about alleged irregularities in railway examination, read- 10 big things
The drug price watchdog NPPA is the body that regulates the prices of drugs under the purview of NLEM and oversees the exercise of curbing the prices of essential drugs by fixing ceilings. The objective behind this move of the government is to bring under price control those medicines whose demand is high and consumers spend more personal disposable income.
Union Health Minister Mansukh Mandaviya reviewed the list and expressed his views, an official said. They have asked us to look for new molecules which are in high demand in the market. Also he has said to remove those molecules which are not often sold.
The official further said that the new list will include those medicines which cost a lot but are life saving and are used by the public. Let us tell you that for example a 1,000 mg vial of meropenem is sold for Rs 2,979, which is quite high.
This medication is an antibiotic used to treat serious infections of the skin, lungs, abdomen, blood and brain and is most commonly used to treat critically ill patients admitted to the hospital. The major brands that make meropenem are AstraZeneca, Cipla, Macleods and Lupine.
,